Whitehawk Therapeutics, Inc. (WHWK) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Whitehawk Therapeutics reported revenue of $7.1M, down 72.5% from $26.0M the year before. Net income was -$20.6M (a -288.3% net margin), or -$0.33 per diluted share. Gross margin was 89.4% and operating margin was -1601.1%. Operating activities generated -$97.4M of cash, leaving -$98.0M of free cash flow. At fiscal year end, Whitehawk Therapeutics held $150.8M in total assets against $14.5M in total liabilities, including $37.6M of cash and equivalents.
Open the full interactive Whitehawk Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Whitehawk Therapeutics Key Stats
| Share Price | $3.02 |
|---|---|
| Market Cap | $250.3M |
| Revenue YoY Growth | -72.5% |
| 52-Week Range | $1.97 – $5.10 |
| Shares Outstanding | 82.9 million (basic, 2026 Q2) |
Whitehawk Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $15.0M | $1.1M | $15.2M | $24.4M | $26.0M | $7.1M |
| Cost of Goods Sold | — | — | $1.3M | $2.8M | $3.0M | $760,000 |
| Gross Profit | — | — | $13.9M | $21.5M | $23.0M | $6.4M |
| Operating Income | -$6.4M | -$111.2M | -$62.7M | -$71.9M | -$67.5M | -$114.4M |
| Pre-Tax Income | -$4.3M | -$110.1M | -$60.5M | -$65.8M | -$63.7M | -$20.6M |
| Income Tax | — | $2,000 | $0 | $0 | $0 | $0 |
| Net Income | -$4.3M | -$110.1M | -$60.5M | -$65.8M | -$63.7M | -$20.6M |
| Diluted EPS | -$1.50 | -$12.41 | -$2.69 | -$2.44 | -$2.36 | -$0.33 |
Whitehawk Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$17.7M | -$23.3M | -$22.2M | -$16.6M |
| Diluted EPS | -$0.26 | -$0.38 | -$0.32 | -$0.20 |
Whitehawk Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $42.6M | $149.0M | $39.0M | $62.9M | $28.7M | $37.6M |
| Current Assets | $44.7M | $151.3M | $180.0M | $124.6M | $61.3M | $149.0M |
| Total Assets | $44.9M | $157.9M | $184.2M | $132.4M | $70.3M | $150.8M |
| Current Liabilities | $1.9M | $15.3M | $18.8M | $26.4M | $17.1M | $14.5M |
| Total Liabilities | $1.9M | $21.5M | $25.9M | $27.2M | $17.8M | $14.5M |
| Shareholders' Equity | $43.1M | $136.4M | $158.4M | $105.2M | $52.5M | $136.3M |
Whitehawk Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$5.4M | -$22.4M | -$49.6M | -$59.7M | -$59.5M | -$97.4M |
| Cash From Investing | -$19,025 | $25.2M | -$132.9M | $83.2M | $25.2M | $11.9M |
| Cash From Financing | $9.5M | $141.8M | $72.6M | $326,000 | $130,000 | $94.4M |
| Free Cash Flow | -$5.4M | -$22.5M | -$50.1M | -$63.6M | -$61.2M | -$98.0M |
| Dividends Paid | — | $4.4M | $0 | — | — | — |
Figures from Whitehawk Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Whitehawk Therapeutics financials page for every line item.
Whitehawk Therapeutics Company Profile
| Ticker | WHWK |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Morristown, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001422142 |
Frequently Asked Questions
What was Whitehawk Therapeutics' revenue in fiscal 2025?
Whitehawk Therapeutics (WHWK) reported revenue of $7.1M for fiscal 2025.
What is Whitehawk Therapeutics' annual revenue history?
Whitehawk Therapeutics' annual revenue by fiscal year: 2020: $15.0M; 2021: $1.1M; 2022: $15.2M; 2023: $24.4M; 2024: $26.0M; 2025: $7.1M.
What was Whitehawk Therapeutics' net income in fiscal 2025?
Whitehawk Therapeutics reported net income of -$20.6M for fiscal 2025.
What was Whitehawk Therapeutics' earnings per share (EPS) in fiscal 2025?
Whitehawk Therapeutics' diluted EPS was -$0.33 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Whitehawk Therapeutics generate in fiscal 2025?
Whitehawk Therapeutics generated -$98.0M of free cash flow in fiscal 2025.
What was Whitehawk Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Whitehawk Therapeutics reported revenue of $0.
How many shares of Whitehawk Therapeutics are outstanding?
Whitehawk Therapeutics reported a weighted average of 82.9 million basic shares outstanding in 2026 Q2.
What is Whitehawk Therapeutics' market cap?
Based on its latest closing price, Whitehawk Therapeutics (WHWK) has a market capitalization of about $250.3M.
When does Whitehawk Therapeutics' fiscal year end?
Whitehawk Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Whitehawk Therapeutics headquartered?
Whitehawk Therapeutics lists its business address in Morristown, New Jersey in its SEC filings.